AN2 Therapeutics, Inc. (ANTX): R&D Expense
$24.77M
Year ended 2025-12-31
$26.64M
Trailing 12 months to 2026-06-30
-4.6%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.77M | -38.8% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $40.49M | -26.2% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $54.87M | +92.5% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $28.51M | +76.5% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $16.16M | n/a | 2023-03-29, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $24.77M | -38.8% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $48.26M | +10.2% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $24.61M | +29.2% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $7.98M | +10.9% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $22.84M | +180.2% |
Compare ANTX, LFVN, OKUR, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗